Evaluating the Validity and Reliability of Persian Version of The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Colorectal Cancer (EORTC QLQ-CR29)

Document Type : Original Article (s)

Authors

1 Researcher, Medical Students’ Research Center, Isfahan University of Medical Sciences, Isfahan, Iran

2 Associate Professor, Department of Community and Preventive Medicine, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

3 Professor, Department of Community and Preventive Medicine, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

4 Associate Professor, Department of Radiotherapy-Oncology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

5 Isfahan Milad Hospital, Isfahan, Iran

6 Poursina Hakim Research Institution, Isfahan, Iran

7 Professor, Department of Internal Medicine, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

Abstract

Background: The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Colorectal Cancer (EORTC QLQ-CR29) is developed to specifically evaluate the quality of life in patients with colorectal cancer. In this study, we aimed to validate the QLQ-CR29 in Iranian patients with Persian language linguistically and to determine its psychometric properties.Methods: This was a linguistic validation study. The QLQ-CR29 was translated by standard forward-backward translation method. After a pilot study with 15 patients, 100 patients with colorectal cancer completed the QLQ-CR29 along with the EORTC QLQ-C30 and the MD Anderson Symptom Inventory (MDASI) and the psychometric properties of the QLQ-CR29 were evaluated.Findings: A hundred of patients with colorectal cancer participated in the main study with the mean age of 60.4 ± 13.4 year; 64% were men. Cronbach’s alpha was 0.89 for the whole QLQ-CR29 and ranged from 0.65 to 0.98 for the subscales. In all the multi-item subscales, the correlation of the item with its corresponding subscale was above 0.4 (r = 0.7 to 0.9). There was a moderate to strong significant correlation between the functional subscales of the QLQ-CR29 and the QLQ-C30 subscales (r = 0.3 to 0.6). In addition, most of the QLQ-CR29 subscales were correlated with MDASI severity and interference subscales (r = 0.2 to 0.5).Conclusion: According to these results, the psychometric properties of the Persian version of the EORTC QLQ-CR29 are acceptable in Iranian society. This questionnaire can be applied for more precise evaluation of quality of life in patients with colorectal cancer in the future studies.

Keywords

References

  1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009; 59(4): 225-49.
  2. Hosseini SV, Izadpanah A, Yarmohammadi H. Epidemiological changes in colorectal cancer in Shiraz, Iran: 1980-2000. ANZ J Surg 2004; 74(7): 547-9.
  3. Yazdizadeh B, Jarrahi AM, Mortazavi H, Mohagheghi MA, Tahmasebi S, Nahvijo A. Time trends in the occurrence of major GI cancers in Iran. Asian Pac J Cancer Prev 2005; 6(2): 130-4.
  4. Moy B, Farraye FA, Jacobson BC. Surveillance after colorectal cancer resection. UpToDate 2009 [Online]. 2014 Apr. [cited 2014 Feb 26]; Available from: URL:http://www.uptodate.com/contents/surveillance-after-colorectal-cancer-resection.
  5. What quality of life? The WHOQOL Group. World Health Organization Quality of Life Assessment. World Health Forum 1996; 17(4): 354-6.
  6. Trask PC1, Hsu MA, McQuellon R. Other paradigms: health-related quality of life as a measure in cancer treatment: its importance and relevance. Cancer J 2009; 15(5): 435-40.
  7. Montazeri A, Goshtasebi A, Vahdaninia M, Gandek B. The Short Form Health Survey (SF-36): translation and validation study of the Iranian version. Qual Life Res 2005; 14(3): 875-82.
  8. Fayers PM, Machin D. Quality of life: The assessment, analysis and interpretation of patient-reported outcomes. 2nd ed. New York, NY: John Wiley & Sons; 2007.
  9. Sprangers MA, te VA, Aaronson NK. The construction and testing of the EORTC colorectal cancer-specific quality of life questionnaire module (QLQ-CR38). European Organization for Research and Treatment of Cancer Study Group on Quality of Life. Eur J Cancer 1999; 35(2): 238-47.
  10. Whistance RN, Conroy T, Chie W, Costantini A, Sezer O, Koller M, et al. Clinical and psychometric validation of the EORTC QLQ-CR29 questionnaire module to assess health-related quality of life in patients with colorectal cancer. Eur J Cancer 2009; 45(17): 3017-26.
  11. Dewolf L, Koller M, Velikova G, Johnson C, Scott N, Bottomley A. EORTC quality of life group translation procedure. 3rd ed. Brussels, Belgium: European Organisation for Research and Treatment (EORTC); 2009.
  12. Safaee A, Moghim DB. Validation study of a quality of life (QOL) questionnaire for use in Iran. Asian Pac J Cancer Prev 2007; 8(4): 543-6.
  13. Cleeland CS, Mendoza TR, Wang XS, Chou C, Harle MT, Morrissey M, et al. Assessing symptom distress in cancer patients: the M.D. Anderson Symptom Inventory. Cancer 2000; 89(7): 1634-46.
  14. 14. Goli F, Scheidt CE, Gholamrezaei A, Farzanegan M. The role of locus of control and attributional style in coping strategies and quality of life among Iranian breast cancer and colorectal cancer patients: a pilot study. Int J Body Mind Culture 2014;1(1): 65-72.
  15. Wild D, Grove A, Martin M, Eremenco S, McElroy S, Verjee-Lorenz A, et al. Principles of Good Practice for the Translation and Cultural Adaptation Process for Patient-Reported Outcomes (PRO) Measures: report of the ISPOR Task Force for Translation and Cultural Adaptation. Value Health 2005; 8(2): 94-104.
  16. Foroutan M, Rahimi N, Tabatabaeifar M, Darvishi M, Hashemi M, Hossein-Panah F, et al. Clinical features of colorectal cancer in Iran: a 15-year review. J Dig Dis 2008; 9(4): 225-7.
  17. Pahlavan PS, Jensen K. A short impact of epidemiological features of colorectal cancer in Iran. Tumori 2005; 91(4): 291-4.
  18. Ansari R, Mahdavinia M, Sadjadi A, Nouraie M, Kamangar F, Bishehsari F, et al. Incidence and age distribution of colorectal cancer in Iran: results of a population-based cancer registry. Cancer Lett 2006; 240(1): 143-7.
  19. Azadeh S, Moghimi-Dehkordi B, Fatem SR, Pourhoseingholi MA, Ghiasi S, Zali MR. Colorectal cancer in Iran: an epidemiological study. Asian Pac J Cancer Prev 2008; 9(1): 123-6.
  20. Allameh Z, Davari M, Emami MH. Cost-effectiveness analysis of colorectal cancer screening methods in Iran. Arch Iran Med 2011; 14(2): 110-4.
  21. Fatemi SR, Shivarani S, Malek FN, Vahedi M, Maserat E, Iranpour Y, et al. Colonoscopy screening results in at risk Iranian population. Asian Pac J Cancer Prev 2010; 11(6): 1801-4.
  22. Peng J, Shi D, Goodman KA, Goldstein D, Xiao C, Guan Z, et al. Early results of quality of life for curatively treated rectal cancers in Chinese patients with EORTC QLQ-CR29. Radiat Oncol 2011; 6: 93.
  23. Arraras JI, Suarez J, Arias dl, V, Vera R, Asin G, Arrazubi V, et al. The EORTC Quality of Life questionnaire for patients with colorectal cancer: EORTC QLQ-CR29 validation study for Spanish patients. Clin Transl Oncol 2011; 13(1): 50-6.
  24. Thaysen HV, Jess P, Laurberg S, Groenvold M. Validation of the Danish version of the disease specific instrument EORTC QLQ-CR38 to assess health-related quality of life in patients with colorectal cancer. Health Qual Life Outcomes 2012; 10: 150.
Journal of Isfahan Medical School
Volume 32, Issue 276 - Serial Number 276
January and February 2014
Pages 228-242

Files

History

  • Receive Date: 28 November 2013
  • Revise Date: 29 April 2024
  • Accept Date: 06 April 2022

Share

How to cite

Statistics